Explore Business Standard
Widely used heart disease risk calculators may be failing to identify a large proportion of Indians at risk, with nearly 80 per cent of patients who eventually suffered a heart attack not being classified as 'high-risk' beforehand, according to new research. The research titled "Comparison of ASCVD Risk Prediction Models in STEMI: Insights from a South Asian Cohort" was conducted by a team of scientists from Govind Ballabh Pant Institute of Postgraduate Medical Education and Research, ESIC Medical College, Faridabad, the Delhi Cancer Registry at AIIMS, among others. The study, conducted on 4,975 patients with first-time heart attacks, found significant differences in how five major global risk prediction models categorised individuals, raising concerns over their reliability for South Asian populations. Researchers compared widely used tools such as the Framingham Risk Score (FRS), ACC/AHA ASCVD 2013 model, WHO risk charts, JBS-3 calculator and the newer Predicting Risk of ...
Getting vaccinated against shingles could lower the chances of a cardiovascular event, such as stroke or heart failure, by 23 per cent, according to a study. Protective effects of the vaccine for shingles -- a viral infection that causes painful rashes -- could last for up to eight years and be stronger among men and people aged under 60. Researchers, led by those from the Kyung Hee University's college of medicine, South Korea, looked at over 12 lakh residents of the country, aged at least 50. Data on shingles vaccination status was collected from 2012 onwards and analysed together with cardiovascular health and lifestyle. Published in the European Heart Journal, the study is "one of the largest and most comprehensive" to provide evidence at a population level, allowing the team to look at the link between vaccination and 18 different types of cardiovascular disease. "There are several reasons why the shingles vaccine may help reduce heart disease. A shingles infection can cause .
Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...